ClinicalTrials.gg
RecruitingNCT05714839DynaMMic-1Updated Aug 19, 2026

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

A Phase 1/2 interventional study of Belantamab and Belantamab mafodotin in Multiple Myeloma, sponsored by GlaxoSmithKline. Recruiting at 44 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Planned enrollment
9th of 49
123 · median 50
Started
2023
with 3 others
Phase 1/2
17 of 49
3 open now
Primary completion
2028-08
later than 23 of 34 live
Registered
28th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 9th largest by planned enrollment, is one of 4 that started in 2023, is one of 17 in phase 1/2, reaches primary completion later than 23 of the 34 other live ones, and was the 28th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

The study consists of three parts:

  • Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+).
  • Part 2: The primary purpose of this part is to evaluate the safety, tolerability, and clinical activity of different doses of belantamab in combination with a fixed dose of Belantamab mafodotin (delivered as separate drugs) in participants with RRMM who have received at least 3 prior therapies (4L+).
  • Part 3: The Primary purpose of this part will evaluate the clinical activity of a selected dose of the belantamab in combination with the pomalidomide-dexamethasone (Pd) standard of care (SoC) backbone. The study will focus on participants with multiple myeloma who have undergone at least one prior line of therapy, including treatment with lenalidomide.
03

Conditions studied

  • Multiple Myeloma

Keywords

  • Belantamab
  • Belantamab Mafodotin
  • Relapsed or Refractory Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants at the time of signing the Form (ICF) are at least 18 years old or are of the legal age of consent in the jurisdiction in which the study is taking place.
  • Participants who have or cytologically confirmed diagnosis of Multiple Myeloma (MM), as defined by the international myeloma working group (IMWG) and have progressed on or following the last

    • Part 1 and Part 2: Participants who have received at least 3 prior lines of anti-myeloma treatments, including any immunomodulatory drug (IMiDs lenalidomide, pomalidomide or thalidomide), a proteasome inhibitor, and an anti-CD38 monoclonal antibodies (mAb) (either in combination or separately).
    • Part 3: Have received at least 1 prior line of treatment anti-myeloma treatments, including lenalidomide. Prior anti-CD38-containing regimen is not mandated, however no more than 70% of participants recruited may be anti-CD38 naïve.
  • Participants with a history of stem cell transplant (ASCT) are eligible for study participation provided the following eligibility criteria are met:

    • transplant was greater than (>)100 days prior to screening.
    • No active bacterial, viral, or fungal infection(s) present
  • -performance status (ECOG-PS) of 0 to 2.
  • defined as at least ONE of the following:

    • Serum M-protein concentration greater than or equal to (>=) 0.5 gram (g)/ deciliter (dL) (>=5 gram/liter [g/L])
    • Urine M-protein excretion >=200 milligram (mg)/24 hours (>=0.2 g/24 hours)
    • Serum free light chain (FLC) assay: involved FLC level >=10 mg/dL (>=100 milligrams per liter [mg/L]) and an abnormal serum FLC ratio (less than [\<]0.26 or >1.65)
  • Have adequate organ system function as defined by the laboratory assessments
  • All prior treatment-related toxicities (defined by National Cancer Institute-Common Toxicity Criteria for Adverse Events [], v5.0, 2017) must be Grade less than or equal to (\<=)1 at the time of screening except for alopecia (any grade), neuropathy (Grade \<=2), or endocrinopathy managed with replacement therapy (any grade).
  • Participants or legally authorized representative (LAR) (if applicable per local regulation) capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • Male Participants (for parts 1b, 2 and 3):
  • use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male Participants enrolled in part 1 (and expansion) cohort receiving belantamab monotherapy are not required to use contraception
  • Male participants are eligible to participate in parts 2 and 3 if they agree to the following during the intervention period and for at least 6 months after the last dose of study intervention to allow for clearance of any altered sperm:

    • Refrain from donating fresh unwashed semen PLUS either:

      • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR
      • Must agree to use contraception/barrier as detailed below
      • Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \<1 percent (%) per year when having sexual intercourse with POCBP who is not currently pregnant. Male participants should also use a condom when having sexual intercourse with pregnant females.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

    • Is NOT a Participant of (POCBP) or
    • Is a POCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency, 30 days prior to treatment start, during the intervention period and for 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
  • Part 3: Due to pomalidomide being a thalidomide analogue with a risk for embryofetal toxicity and prescribed under a pregnancy prevention/controlled distribution program, POCBP will be eligible if they commit either to abstain continuously from heterosexual sexual intercourse or use two methods of reliable birth control (one method that is highly effective plus an additional barrier method), beginning at least 4 weeks prior to initiating treatment with pomalidomide, during therapy, during dose interruptions and continuing for at least 4 weeks following discontinuation of pomalidomide treatment. Thereafter, POCBP must use one contraceptive method that is highly effective (with a failure rate of less than (\<)1% per year) for a further 3 months (total 4 months).
  • The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention
  • All POCBP must agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period.

Exclusion criteria

Exclusion criteria

  • Diagnosis of primary Amyloid Light chain (AL) Amyloidosis, active Polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes (POEMS) syndrome, primary plasma cell leukemia.
  • Part 3: Active or history of venous or arterial thromboembolism within the past 3 months. to or unwilling to undergo protocol-required anti-thrombotic prophylaxis
  • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining , or compliance with study procedures.
  • Participant is exhibiting signs of meningeal or central nervous system involvement with MM.
  • Part 2: Current corneal epithelial disease except nonconfluent Superficial punctate keratitis (SPK).
  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
  • Presence of other than disease under study are excluded, except for any other malignancy from which the participant has been disease-free for more than 2 years and, in the opinion of the Principal investigator (PI) and GlaxoSmithKline (GSK) Medical Director, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (MM). Participants on active surveillance or hormone treatment for non- prostate cancer are not excluded. Participants on hormone therapy for non-metastatic breast cancer are not excluded
  • Evidence of cardiovascular risk including any of the following:

    • Evidence of current untreated arrhythmias, including, but not limited to, clinically significant (ECG) abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree Atrioventricular (AV) block.
    • Part 1 dose escalation and Part 2 only: corrected using Fridericia's formula (QTcF) interval >480 millisecond (msec) (QT interval corrected for heart rate according to Fridericia's formula), and/or hypokalemia, and/or family history of long QT syndrome.
    • Part 1 dose expansion and Part 3: Not applicable.
    • History of MI, acute coronary syndromes (including unstable angina), coronary angioplasty, stenting or bypass grafting, all within three months of screening.
    • Class III or IV heart failure as defined by the (NYHA) functional classification system.
    • Uncontrolled hypertension
  • Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to belantamab / belantamab mafodotin or any of the components of the study treatment. History of severe hypersensitivity to other Monoclonal antibodies (mAbs).
  • Active infection requiring antibiotic, antiviral, or antifungal treatment.
  • For serology of surface antigen (HBsAg)+ at screen or within 3 months prior to first dose Japan only: must test Hepatitis B e antigen (HBeAg) and Hepatitis B e antibody (HBeAb). Eligibility verification should be evaluated and agreed with a hepatologist (after they record the approval in the participant medical record).
  • Known (HIV) infection, unless the participant can meet specific criteria.
  • Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel disease, intra-abdominal abscess, or gastrointestinal obstruction.
  • Participants with Hepatitis B virus (HBV) or virus (HCV) will be excluded unless specific criteria can be met.
  • Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible.
  • Part 1: to belantamab mafodotin (confirmed PD as per IMWG criteria while on belantamab mafodotin therapy or within 60 days of completing that treatment). Prior belantamab mafodotin is allowed if it was discontinued due to toxicity which subsequently resolved. Note: Prior treatment with other anti- B-cell maturation antigen (BCMA) directed agents is allowed. Provided there is at least 6-month washout after the last dose of prior anti-BCMA therapy.
  • Part 2: Prior belantamab mafodotin therapy is not allowed. Prior treatment with other anti-BCMA directed agents is allowed provided there is at least a 6-month washout after the last dose of prior anti-BCMA therapy .
  • Prior radiotherapy within 2 weeks of start of study therapy.
  • Plasmapheresis within 7 days prior to the first dose of study drug.
  • Prior stem cells transplant.
  • Participants who have received prior Chimeric Antigen Receptor T-cell therapy (CAR-T) therapy with lymphodepletion with chemotherapy within 3 months of screening.
  • Any major surgery (other than bone-stabilizing surgery) within 2 weeks of first dose or has not recovered fully from surgery.
  • Prior treatment with a mAb within 30 days of receiving the first dose of study drugs, or treatment with an agent or approved systemic anti-myeloma therapy (including systemic ) within 14 days or 5 half-lives of receiving the first dose of study drugs, whichever is longer.
  • Part 1 dose escalation only: Has received transfusion of blood products (including or red blood cells) or administration of colony stimulating factors (including Granulocyte colony stimulating factor [G-CSF], Granulocyte-macrophage colony-stimulating factor [GMCSF], recombinant erythropoietin) or any thrombopoietin receptor agonists within 2 weeks before the first dose of study drug. This does not apply for Part 1 Expansion Cohort.
  • Part 3: Prior belantamab, belantamab mafodotin, and pomalidomide therapy are not allowed. Prior treatment with other anti- BCMA directed agents is allowed provided there is at least 6-month washout after the last dose of prior anti-BCMA therapy.
  • Participants must not receive live/ within 30 days prior to first dose of study treatment or whilst receiving belantamab for at least 70 days following last study treatment.
  • Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this trial, unless prospective Independent Review Board (IRB) approval (by chair or designee) is allowing exception to this criterion for a specific participant.
  • The use of other anti-cancer therapy not specified in this protocol, and any investigational agents other than belantamab and belantamab mafodotin, or any other MM Standard of Care (SoC) agents other than pomalidomide or dexamethasone are explicitly prohibited for the duration of the study.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
123 participants (estimated)

Study arms

  • Experimental
    Part 1: Dose escalation and expansion of belantamab monotherapy

    Belantamab will be administered in participants with RRMM until progressive disease (PD)

    Drug: Belantamab

  • Experimental
    Part 2: Belantamab and belantamab mafodotin (delivered as separate drugs) dose range finding

    Participants with RRMM will receive belantamab and belantamab mafodotin

    Drug: Belantamab · Drug: Belantamab mafodotin

  • Experimental
    Part 3: Belantamab +pomalidomide/dexamethasone in 2L+ RRMM

    Participants with RRMM will receive belantamab in combination with pomalidomide-dexamethasone backbone.

    Drug: Belantamab · Drug: Pomalidomide · Drug: Dexamethasone

  • Experimental
    Part 1b: Optional belantamab mafodotin

    Participants enrolled in Part 1 and Part 2 will be dosed until PD after which they will have the option to receive treatment with single agent belantamab mafodotin.

    Drug: Belantamab mafodotin

Interventions

06

What researchers measure

Primary outcomes

  1. Parts 1, 2 and 3: Number of Participants with any Adverse Event

    Time frame: Up to 52 months

  2. Part 1 (Dose escalation cohort) and Part 2: Number of Participants with Dose Limiting Toxicities (DLTs)

    Time frame: Cycle 1 (Each cycle is of 28 days)

  3. Part 1, 2 and 3: Number of Participants with Worst Case Grade Change from Baseline in Laboratory and Vital Sign Parameters

    Time frame: Up to 52 months

  4. Part 2: Number of Participants with severity of ocular events by the Keratopathy Visual Acuity (KVA) scale

    Time frame: Up to 52 months

  5. Part 2: Overall Response Rate (ORR)

    Time frame: Up to 52 months

  6. Part 3: Very Good Partial Response and better rate (VGPR+)

    VGPR+ is defined as the percentage of participants with a confirmed VGPR or better (i.e., VGPR, complete response, stringent complete response).

    Time frame: Up to 52 months

Secondary outcomes

  1. Part 1: Overall Response Rate (ORR)

    Time frame: Up to 52 months

  2. Part 1: Observed Plasma Concentration of belantamab

    Time frame: Up to 52 months

  3. Part 1: Area Under the Curve (AUC) of belantamab

    Time frame: Up to 52 months

  4. Part 1: Maximum Concentration (Cmax) of belantamab

    Time frame: Up to 52 months

  5. Part 1: Number of Participants with Anti-Drug Antibodies (ADA) against belantamab

    Time frame: Up to 52 months

  6. Part 1: Titers of ADA against belantamab

    Time frame: Up to 52 months

  7. Part 2: Duration of Response (DoR)

    Time frame: Up to 52 months

  8. Part 2: Observed Plasma Concentration of Total belantamab

    Time frame: Up to 52 months

  9. Part 2: Area Under the Curve (AUC) of Total belantamab

    Time frame: Up to 52 months

  10. Part 2: Maximum Concentration (Cmax) of Total belantamab

    Time frame: Up to 52 months

  11. Part 2: Observed Plasma Concentration of belantamab mafodotin (ADC)

    Time frame: Up to 52 months

  12. Part 2: Area Under the Curve (AUC) of belantamab mafodotin (ADC)

    Time frame: Up to 52 months

  13. Part 2: Maximum Concentration (Cmax) of belantamab mafodotin (ADC)

    Time frame: Up to 52 months

  14. Part 2: Observed Plasma Concentration of Cys-Monomethyl Auristatin-F (Cys-mcMMAF)

    Time frame: Up to 52 months

  15. Part 2: Area Under the Curve (AUC) of Cys-mcMMAF

    Time frame: Up to 52 months

  16. Part 2: Maximum Concentration (Cmax) of Cys-mcMMAF

    Time frame: Up to 52 months

  17. Part 2: Number of Participants with ADAs against belantamab and belantamab mafodotin

    Time frame: Up to 52 months

  18. Part 2: Titers of ADAs against belantamab and belantamab mafodotin

    Time frame: Up to 52 months

  19. Part 3: Minimal residual disease (MRD) negativity rate in participants achieving at least VGPR

    MRD negativity rate is defined as the percentage of participants who achieve MRD negative status at 10-5 sensitivity threshold assessed by next generation sequencing at least once during the time of confirmed VGPR+ response per International myeloma working group (IMWG) criteria.

    Time frame: Up to 52 months

  20. Part 3: Overall Response Rate (ORR)

    Time frame: Up to 52 months

  21. Part 3: Duration Of Response (DoR)

    Time frame: Up to 52 months

  22. Part 3: Observed Plasma Concentration of Total belantamab

    Time frame: Up to 52 months

  23. Part 3: Area Under the Curve (AUC) of Total belantamab

    Time frame: Up to 52 months

  24. Part 3: Maximum Concentration (Cmax) of Total belantamab

    Time frame: Up to 52 months

  25. Part 3: Number of Participants with ADAs against belantamab

    Time frame: Up to 52 months

  26. Part 3: Titers of ADAs against belantamab

    Time frame: Up to 52 months

07

Study locations

39 of 44 sites recruiting
  • GSK Investigational Site
    Bullhead City, Arizona 86442, United States
    Recruiting
  • GSK Investigational Site
    Los Angeles, California 90027, United States
    Recruiting
  • GSK Investigational Site
    Pembroke Pines, Florida 33024, United States
    Recruiting
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
    Recruiting
  • GSK Investigational Site
    Grand Rapids, Michigan 49546, United States
    Recruiting
  • GSK Investigational Site
    Chapel Hill, North Carolina 27514, United States
    Recruiting
  • GSK Investigational Site
    Wilson, North Carolina 27893, United States
    Recruiting
  • GSK Investigational Site
    Canton, Ohio 44718, United States
    Recruiting
  • GSK Investigational Site
    Chattanooga, Tennessee 37404, United States
    Recruiting
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
    Recruiting
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
    Recruiting
  • GSK Investigational Site
    Capital Federal, C1426ANZ, Argentina
    Recruiting
  • GSK Investigational Site
    Ciudadela, B1702, Argentina
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Rosario, S2002, Argentina
    Recruiting
  • GSK Investigational Site
    San Juan Bautista, B1888AAE, Argentina
    Recruiting
  • GSK Investigational Site
    Viedma, R8500ACE, Argentina
    Recruiting
  • GSK Investigational Site
    Fitzroy, Victoria 3065, Australia
    Recruiting
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Joinville, 89201-260, Brazil
    Recruiting
  • GSK Investigational Site
    Salvador, 41253-190, Brazil
    Recruiting
  • GSK Investigational Site
    São Paulo, 04537-080, Brazil
    Recruiting
  • GSK Investigational Site
    Suzhou, China
    Recruiting
  • GSK Investigational Site
    Beersheba, 84101, Israel
    Recruiting
  • GSK Investigational Site
    Jerusalem, 9112001, Israel
    Recruiting
  • GSK Investigational Site
    Ramat Gan, 52621, Israel
    Recruiting
  • GSK Investigational Site
    Aomori, 030-8553, Japan
    Recruiting
  • GSK Investigational Site
    Chiba, 277-8577, Japan
    Recruiting
  • GSK Investigational Site
    Kanagawa, 221-0855, Japan
    Recruiting
  • GSK Investigational Site
    Osaka, 545-8586, Japan
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Tokyo, 105-8471, Japan
    Recruiting
  • GSK Investigational Site
    Yamagata, 990-9585, Japan
    Recruiting
  • GSK Investigational Site
    Gdansk, 80-214, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Lublin, 20-081, Poland
    Recruiting
  • GSK Investigational Site
    Kuils River, Western Cape 7580, South Africa
    Recruiting
  • GSK Investigational Site
    Seoul, 137-701, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 138-736, South Korea
    Recruiting
  • GSK Investigational Site
    Changhua, 500, Taiwan
    Recruiting
  • GSK Investigational Site
    Kaohsiung City, 807, Taiwan
    Recruiting
  • GSK Investigational Site
    Taipei, 100, Taiwan
    Recruiting
  • GSK Investigational Site
    Istanbul, 34010, Turkey (Türkiye)
    Recruiting
  • GSK Investigational Site
    Kayseri, 38039, Turkey (Türkiye)
    Recruiting
  • GSK Investigational Site
    Leicester, LE1 5WW, United Kingdom
    Recruiting
  • GSK Investigational Site
    Oxford, OX3 7LE, United Kingdom
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Plymouth, PL6 8DH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Aug 2028, 61 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 61 months is close to that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2023
First posted
Feb 6, 2023
StartActual
Jun 14, 2023
Primary completionEst.
Aug 3, 2028
CompletionEst.
Aug 3, 2028
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05714839
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 6, 2023
Start date
Jun 14, 2023
Primary completion
Aug 3, 2028 (estimated)
Completion
Aug 3, 2028 (estimated)
Last update
Aug 19, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belantamab · Belantamab mafodotin

Start the discussion